Cerus Corporation (NASDAQ:CERS) is set to announce third quarter earning results on Thursday 29th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CERS to report 3Q20 loss of $ 0.1 per share.
For the full year, analysts anticipate top line of $ 112.46 million, while looking forward to loss of $ 0.4 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 89.00 million ~ $ 93.00 million
Click Here For More Historical Outlooks Of Cerus Corporation
Previous Quarter Performance
Cerus Corporation reported loss for the second quarter of $ 0.09 per share, from the revenue of $ 21.50 million. The quarterly revenues reduced 4.36 percent compared with the same quarter last year. According to street consensus, CERS was expected to report 2Q20 loss of $ 0.11 per share from revenue of $ 25.89 million. The bottom line results beat street analysts by $ 0.02 or 18.18 percent, at the same time, top line results fell short of analysts by $ 4.39 million or 16.96 percent.
Stock Performance
Shares of Cerus Corporation traded low $ -0.41 or -6.88 percent on Wednesday, reaching $ 5.55 with volume of 1.44 million shares. Cerus Corporation has traded high as $ 5.90 and has cracked $ 5.55 on the downward trend
According to the previous trading day, closing price of $ 5.55, representing a 119.93 % increase from the 52 week low of $ 2.71 and a 24.94 % decrease over the 52 week high of $ 7.94.
The company has a market capital of $ 922.25 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Cerus Corporation will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cerus.com
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.
